HomeAI Analysis (OSIEL)
Explore evidence, research context, hypotheses, uncertainty, and next-step scientific recommendations across the OncoGon portfolio.
21 linked records · approval and training eligibility are separate governance states
Select a record to inspect scientific context
| Evidence ID | Title | Type | Asset | Study | Strength | Approval | Training Eligibility | Owner | Updated |
|---|---|---|---|---|---|---|---|---|---|
| OGC-2401 | Novel small molecule | Asset Evidence | OGC-2401 | BC-001 | High | Under Review | Not Reviewed | Dr. S. Mokoena | 2026-10-03 |
| HYP-001 | ATM/Chk1 pathway research hypothesis | Research Note | OGC-2401 | BC-001 | Medium | Under Review | Not Reviewed | Dr. S. Mokoena | 2026-10-01 |
| EV-2401-01 | ATM/Chk1 pathway literature review | External Literature | OGC-2401 | BC-001 | High | Approved | Evidence Only | Dr. J. Patel | 2026-09-18 |
| EV-2401-02 | 3D spheroid response at Day 7 | Response Analysis | OGC-2401 | BC-001 | High | Under Review | Evidence Only | Dr. S. Mokoena | 2026-10-03 |
| EV-2401-03 | Dose response validation | Asset Evidence | OGC-2401 | BC-002 | High | Approved | Evidence Only | Dr. M. Rossi | 2026-09-29 |
| EV-2401-04 | BRCA pathway biomarker panel | Asset Evidence | OGC-2401 | BC-001 | Medium | Needs Attention | Evidence Only | Dr. L. Chen | 2026-09-21 |
| EV-2401-05 | Replication stress mechanism memo | Asset Evidence | OGC-2401 | — | Medium | Approved | Evidence Only | Dr. S. Mokoena | 2026-09-13 |
| EV-2401-06 | Early ADMET screen | Asset Evidence | OGC-2401 | — | Low | Draft | Evidence Only | Dr. J. Patel | 2026-09-09 |
| EV-2401-07 | TNBC opportunity landscape | Commercial Evidence | OGC-2401 | — | Medium | Restricted | Evidence Only | N. Daniels | 2026-09-04 |
| BC-001 | Breast Cancer Spheroid Response Study | Experiment | OGC-2401 | BC-001 | High | Under Review | Evidence Only | Dr. S. Mokoena | 2026-10-03 |
| IMG-BC001-017 | BC-001 Drug B Day 7 brightfield acquisition | Imaging | OGC-2401 | BC-001 | High | Approved | Evidence Only | Imaging Core | 2026-10-03 |
| SEG-BC001-047 | Drug B spheroid segmentation review | Segmentation / QC | OGC-2401 | BC-001 | Medium | Under Review | Evidence Only | Unassigned | 2026-10-03 |
| RESP-BC001-B-D7 | Drug B Day 7 response analysis | Response Analysis | OGC-2401 | BC-001 | High | Under Review | Evidence Only | Dr. S. Mokoena | 2026-10-03 |
| DS-2401-01 | Day 7 spheroid images | Dataset | OGC-2401 | BC-001 | High | Approved | Evidence Only | Imaging Core | 2026-10-03 |
| DS-2401-02 | Dose response measurements | Dataset | OGC-2401 | BC-002 | High | Approved | Not Reviewed | Dr. M. Rossi | 2026-09-29 |
| DS-2401-03 | BRCA expression panel | Dataset | OGC-2401 | BC-001 | Medium | Under Review | Restricted | Molecular Core | 2026-09-21 |
| DS-2401-04 | Annotated segmentation masks | Dataset | OGC-2401 | BC-001 | Medium | Under Review | Excluded | Imaging Core | 2026-09-18 |
| DS-2401-05 | Validated image features | Dataset | OGC-2401 | BC-001 | High | Approved | Eligible | Data Governance | 2026-09-16 |
| EV-024 | 3D response evidence package | Scientific Review | OGC-2401 | BC-001 | High | Approved | Evidence Only | Dr. L. Chen | 2026-10-02 |
| NOTE-2401-03 | Replicate confirmation note | Research Note | OGC-2401 | BC-001 | Medium | Draft | Not Reviewed | Dr. S. Mokoena | 2026-09-30 |
| REV-BC001-01 | Scientific review request | Review Decision | OGC-2401 | BC-001 | Medium | Under Review | Excluded | Dr. L. Chen | 2026-10-03 |
RESP-BC001-B-D7
18% viability and −71% tumour-size change; Strong Response is illustrative and under review.
Observed response summary requires replicate confirmation and scientist interpretation.
Illustrative links between asset, study, image, segmentation, response, dataset, hypothesis, and review
Graph links represent illustrative frontend relationships. Select a node to inspect its source.
Upload ≠ Approval ≠ Training ≠ Deployment